Faricimab

Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) . Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951) . Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) [1][2][3][4][5].

Product Specifications

CAS Number

[1607793-29-2]

Product Name Alternative

RG7716; RO-6867461

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/faricimab.html

Purity

97.97

Solubility

H2O

Smiles

[Faricimab]

Molecular Weight

(146.16 kDa)

References & Citations

[1]Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126 (8) :1155-1170.|[2]Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30 (3) :193-200. |[3]Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10 (1) :5.|[4]Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464.|[5]Jørstad ØK, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9 (1) :65.